Cencora Inc COR

$331.00 -7.48 (-2.21%)

Valuation

Market cap
63,163,736,000
Revenue TTM
$321,332,810,000
Net income TTM
$1,554,170,000
PE ratio
19.74
Forward PE
17.12
Profit margin
0.48%
Debt to equity
3.62

Trading

Volume
1,168,200
Avg volume
1,213,950
Day's range
$330.31 – $338.07
Shares out
190,827,000
Stochastic %K
21%
Beta
0.58
Analysts
Strong Sell
Price target
$366.85

Price

Company profile

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical c...

Show more

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

Industry
Medical Distribution
Sector
Healthcare
Phone
610 727 7000
Website
https://www.cencora.com
Address
1 West First Avenue, Conshohocken, United States

Latest news

Stocktwits

thatsolardude365 Oct 24, 2:21 PM
$COR: November is a week out, and Cencora filers are still waiting for a confirmed payout start. The $40M breach deal is final-approved; the administrator's Oct. 16 update only anticipates distribution then. Open Class Actions.
0 replies
thatsolardude365 Oct 23, 10:21 AM
$COR: Anaya, 2:24-cv-02961 in E.D. Pa., is why Cencora checks are still pending. The administrator cites the large volume of claims still being processed, with distribution now eyed for November 2026. Claims closed. Open Class Actions.
0 replies
thatsolardude365 Oct 22, 12:37 AM
$COR: what Cencora filers chose matters now. Documented-loss claims can reach $5,000, no-documentation claims get a pro rata cash share, and California cash payments get a multiplier. Payouts slated for November. Open Class Actions.
0 replies
Fotstocks Oct 21, 4:03 PM
$COSM: priced like it’s dying, guided like a compounder. Market cap is about $30M, roughly 0.33x FY26 sales of $90M+. Giant, slow-growth drug distributors like $MCK and $COR trade at 0.2–0.3x. COSM gets the same multiple while growing many times faster and owning a high-margin CMO business and proprietary brands that would trade at multiples of sales on their own. The market is paying for the distributor and getting everything else free. Against the 2029 guide (32% revenue CAGR): • Revenue $200M → 0.15x • Adj. EBITDA $44M → under 1x • Operating cash flow $24M → about 1.25x Zacks values COSM at $4.50. My target is $2: about a $200M market cap, or 4.5x 2029 EBITDA guidance. That’s still a discount.
0 replies
filecrux Oct 21, 12:06 PM
$COR Cencora expects to pay ~$1.7B cash to raise its stake in cancer network AON to 75%.
0 replies
thatsolardude365 Oct 19, 11:57 AM
$COR: another delay on Cencora payouts. The $40M data breach deal first pointed to August, then September, then October. The Oct. 16 update now says November 2026. Claims closed. Open Class Actions.
0 replies
thatsolardude365 Oct 16, 10:28 PM
$COR: still no confirmed start to Cencora payouts. The $40M data breach deal is final-approved, the administrator targets October 2026 to begin, but as of Oct 14 no source confirmed payments had begun. Open Class Actions.
0 replies
thatsolardude365 Oct 15, 3:36 PM
$COR payout update: the Sept. 29 administrator note moved Cencora's $40M data breach distribution to October 2026, still processing a large claim volume. Claims closed Jan. 19. Filed? Watch for payment. Open Class Actions.
0 replies